

# Karsten Heekeren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/50448/publications.pdf>

Version: 2024-02-01

68  
papers

2,521  
citations

172207

29  
h-index

205818

48  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3576  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prepulse inhibition in psychiatric disorders – Apart from schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 445-452.	1.5	272
2	Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers. <i>Pharmacopsychiatry</i> , 2005, 38, 301-311.	1.7	172
3	Aberrant Coupling Within and Across the Default Mode, Task-Positive, and Salience Network in Subjects at Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2014, 40, 1095-1104.	2.3	149
4	Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. <i>Psychopharmacology</i> , 2008, 199, 77-88.	1.5	127
5	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. <i>JAMA Psychiatry</i> , 2021, 78, 195.	6.0	125
6	Well-Being Among Persons at Risk of Psychosis: The Role of Self-Labeling, Shame, and Stigma Stress. <i>Psychiatric Services</i> , 2014, 65, 483-489.	1.1	94
7	An fMRI approach to particularize the frontoparietal network for visuomotor action monitoring: Detection of incongruence between test subjects' actions and resulting perceptions. <i>NeuroImage</i> , 2007, 34, 332-341.	2.1	78
8	Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. <i>Behavioural Pharmacology</i> , 1998, 9, 561-566.	0.8	75
9	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. <i>JAMA Psychiatry</i> , 2021, 78, 753.	6.0	74
10	The Negative Symptoms of Schizophrenia: Category or Continuum?. <i>Psychopathology</i> , 2011, 44, 345-353.	1.1	68
11	Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. <i>Psychopharmacology</i> , 2005, 180, 607-611.	1.5	66
12	Stigma as a stressor and transition to schizophrenia after one year among young people at risk of psychosis. <i>Schizophrenia Research</i> , 2015, 166, 43-48.	1.1	65
13	Symptom dimensions are associated with reward processing in unmedicated persons at risk for psychosis. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 382.	1.0	56
14	Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: Evidence from an 18-month longitudinal functional magnetic resonance imaging study. <i>Biological Psychiatry</i> , 2004, 56, 349-355.	0.7	55
15	Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. <i>Journal of Psychopharmacology</i> , 2010, 24, 1515-1524.	2.0	51
16	Triple Network Model Dynamically Revisited: Lower Salience Network State Switching in Pre-psychosis. <i>Frontiers in Physiology</i> , 2020, 11, 66.	1.3	49
17	Correlation of passivity symptoms and dysfunctional visuomotor action monitoring in psychosis. <i>Brain</i> , 2008, 131, 2783-2797.	3.7	46
18	Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. <i>Journal of Psychopharmacology</i> , 2007, 21, 312-320.	2.0	45

#	ARTICLE	IF	CITATIONS
19	Effects of the Hallucinogen Psilocybin on Covert Orienting of Visual Attention in Humans. <i>Neuropsychobiology</i> , 2002, 45, 205-212.	0.9	42
20	Attentional Modulation of Prepulse Inhibition: A New Startle Paradigm. <i>Neuropsychobiology</i> , 2004, 49, 88-93.	0.9	42
21	Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. <i>NPJ Schizophrenia</i> , 2016, 2, 16033.	2.0	42
22	TRIMAGE: A dedicated trimodality (PET/MR/EEG) imaging tool for schizophrenia. <i>European Psychiatry</i> , 2018, 50, 7-20.	0.1	40
23	Inhibition of Return in the Human 5HT2A Agonist and NMDA Antagonist Model of Psychosis. <i>Neuropsychopharmacology</i> , 2006, 31, 431-441.	2.8	38
24	Longitudinal course of self-labeling, stigma stress and well-being among young people at risk of psychosis. <i>Schizophrenia Research</i> , 2014, 158, 82-84.	1.1	38
25	Pathways between stigma and suicidal ideation among people at risk of psychosis. <i>Schizophrenia Research</i> , 2016, 172, 184-188.	1.1	37
26	Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. <i>Psychopharmacology</i> , 2008, 200, 573-583.	1.5	35
27	Attitudes towards help-seeking and stigma among young people at risk for psychosis. <i>Psychiatry Research</i> , 2013, 210, 1313-1315.	1.7	34
28	Early Recognition of High Risk of Bipolar Disorder and Psychosis: An Overview of the ZInEP – “Early Recognition” Study. <i>Frontiers in Public Health</i> , 2014, 2, 166.	1.3	32
29	Blunted inhibition of return in schizophrenia – evidence from a longitudinal study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 389-396.	2.5	31
30	Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives. <i>Schizophrenia Research</i> , 2007, 97, 35-42.	1.1	28
31	Neurocognitive profiles in help-seeking individuals: comparison of risk for psychosis and bipolar disorder criteria. <i>Psychological Medicine</i> , 2014, 44, 3543-3555.	2.7	27
32	Deficient inhibition of return in schizophrenia – further evidence from an independent sample. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 42-49.	2.5	24
33	Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. <i>Psychological Medicine</i> , 2016, 46, 1069-1078.	2.7	23
34	Self-labelling and stigma as predictors of attitudes towards help-seeking among people at risk of psychosis: 1-year follow-up. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 79-82.	1.8	21
35	Checking the predictive accuracy of basic symptoms against ultra high-risk criteria and testing of a multivariable prediction model: Evidence from a prospective three-year observational study of persons at clinical high-risk for psychosis. <i>European Psychiatry</i> , 2017, 45, 27-35.	0.1	21
36	Changes in neurocognitive functioning during transition to manifest disease: comparison of individuals at risk for schizophrenic and bipolar affective psychoses. <i>Psychological Medicine</i> , 2015, 45, 2123-2134.	2.7	20

#	ARTICLE	IF	CITATIONS
37	Stigma and suicidal ideation among young people at risk of psychosis after one year. <i>Psychiatry Research</i> , 2016, 243, 219-224.	1.7	20
38	mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia. <i>Human Brain Mapping</i> , 2020, 41, 2762-2781.	1.9	20
39	Course of psychotic symptoms, depression and global functioning in persons at clinical high risk of psychosis: Results of a longitudinal observation study over three years focusing on both converters and non-converters. <i>Schizophrenia Research</i> , 2017, 189, 19-26.	1.1	18
40	Neurocognition in help-seeking individuals at risk for psychosis: Prediction of outcome after 24 months. <i>Psychiatry Research</i> , 2016, 246, 188-194.	1.7	16
41	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , 2017, 8, 292.	1.3	16
42	Cortical Volume Differences in Subjects at Risk for Psychosis Are Driven by Surface Area. <i>Schizophrenia Bulletin</i> , 2020, 46, 1511-1519.	2.3	16
43	Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users. <i>Psychopharmacology</i> , 2004, 173, 418-424.	1.5	12
44	Evaluation of trait adjectives and ego pathology in schizophrenia: An N400 study. <i>Psychiatry Research</i> , 2014, 215, 533-539.	1.7	12
45	The Loudness Dependence of Auditory Evoked Potentials (LDAEP) in individuals at risk for developing bipolar disorders and schizophrenia. <i>Clinical Neurophysiology</i> , 2016, 127, 1342-1350.	0.7	12
46	Polygenic risk scores across the extended psychosis spectrum. <i>Translational Psychiatry</i> , 2021, 11, 600.	2.4	11
47	Pregabalin-Induced Suicidal Ideations. <i>Pharmacopsychiatry</i> , 2011, 44, 119-119.	1.7	10
48	Early somatosensory processing in individuals at risk for developing psychoses. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 308.	1.0	10
49	Psychiatric Acute Day Hospital as an Alternative to Inpatient Treatment. <i>Frontiers in Psychiatry</i> , 2020, 11, 471.	1.3	10
50	Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans. <i>Psychopharmacology</i> , 2012, 221, 389-396.	1.5	9
51	Pure animal phobia is more specific than other specific phobias: epidemiological evidence from the Zurich Study, the ZInEP and the PsyCoLaus. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 567-577.	1.8	9
52	Simultaneous PET-MR-EEG: Technology, Challenges and Application in Clinical Neuroscience. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 377-385.	2.7	9
53	Frontal brain activity in individuals at risk for schizophrenic psychosis and bipolar disorder during the emotional Stroop task – an fNIRS study. <i>NeuroImage: Clinical</i> , 2020, 26, 102232.	1.4	9
54	Influence of demographic characteristics on attenuated positive psychotic symptoms in a young, help-seeking, at-risk population. <i>Microbial Biotechnology</i> , 2019, 13, 53-56.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Mismatch negativity: Alterations in adults from the general population who report subclinical psychotic symptoms. <i>European Psychiatry</i> , 2016, 34, 9-16.	0.1	7
56	Borderline Personality Pathology in an At Risk Mental State Sample. <i>Frontiers in Psychiatry</i> , 2019, 10, 838.	1.3	7
57	mGluR5 binding changes during a mismatch negativity task in a multimodal protocol with [11C]ABP688 PET/MR-EEG. <i>Translational Psychiatry</i> , 2022, 12, 6.	2.4	7
58	White matter microstructure and the clinical risk for psychosis: A diffusion tensor imaging study of individuals with basic symptoms and at ultra-high risk. <i>NeuroImage: Clinical</i> , 2022, 35, 103067.	1.4	7
59	Neuregulin 1 (NRG1) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis. <i>Psychiatry Research</i> , 2018, 266, 143-146.	1.7	4
60	Early Somatosensory Processing Over Time in Individuals at Risk to Develop Psychosis. <i>Frontiers in Psychiatry</i> , 2019, 10, 47.	1.3	2
61	Inhibition of return (IOR) in patients with schizophrenia and cannabis use. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 65-72.	2.5	1
62	Psychopathological effects of S-ketamine and dimethyltryptamine (DMT) in humans: a double-blind, cross-over human experimental study of the NMDA antagonist and the 5HT2A agonist model of psychosis. <i>Pharmacopsychiatry</i> , 2005, 38, .	1.7	1
63	CORRELATION OF PSYCHOTIC PASSIVITY SYMPTOMS AND IMPAIRED VISUOMOTOR ACTION MONITORING: EVIDENCE FROM BEHAVIORAL AND fMRI DATA. <i>Schizophrenia Research</i> , 2008, 102, 93-94.	1.1	0
64	Poster #S157 THE COURSE OF NEUROCOGNITIVE FUNCTIONING IN HELPSEEKING INDIVIDUALS: COMPARISON OF RISK FOR PSYCHOSIS AND BIPOLAR DISORDER CRITERIA. <i>Schizophrenia Research</i> , 2014, 153, S146.	1.1	0
65	Poster #M158 NEURAL CORRELATES OF REWARD PROCESSING IN UNMEDICATED PERSONS AT-RISK FOR PSYCHOSIS. <i>Schizophrenia Research</i> , 2014, 153, S247-S248.	1.1	0
66	Trimodal approach (PET/MR/EEG) of response inhibition as a possible biomarker for schizophrenia. <i>European Psychiatry</i> , 2016, 33, S88-S89.	0.1	0
67	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 140-151.	1.1	0
68	Orienting of attention in the 5HT2A agonist and NMDA antagonist model of psychosis. <i>Pharmacopsychiatry</i> , 2005, 38, .	1.7	0